BiologicalDrug
Regdanvimab clinical trials
Also written CT-P59.
How studies write it
Studies that test it under each name
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses regdanvimab is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 InfectionCompletedPhase 2/3CelltrionNCT04602000Written as CT-P59
- This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)CompletedPhase 1CelltrionNCT04593641Written as CT-P59
- To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy SubjectsCompletedPhase 1CelltrionNCT04525079Written as CT-P59
As the comparator · 1 — what is tested is compared with regdanvimab
Codes
What other systems call regdanvimab · ClinicalTrials.gg INT001613
- MeSH (NLM) C000716788regdanvimabOne source NLM
- UNII (FDA) I0BGE6P6I6REGDANVIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q105687595regdanvimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C177084RegdanvimabOne source FDA
- DrugBank DB16405One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000716788 | regdanvimab | One source NLM |
| UNII (FDA) | I0BGE6P6I6 | REGDANVIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q105687595 | regdanvimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C177084 | Regdanvimab | One source FDA |
| DrugBank | DB16405 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.